Rutgers, The State University of New Jersey
New Brunswick, New Jersey
Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center, was established in 1991, began seeing patients in 1993, became an NCI-designated Cancer Center in 1997 and achieved Comprehensive Cancer Center status in 2002. The Cancer Institute of New Jersey integrated into Rutgers University on July 1, 2013 and became an independent unit within the university as a result of the New Jersey Medical and Health Sciences Education Restructuring Act.
Rutgers Cancer Institute of New Jersey delivers advanced comprehensive care for adults and children, conducts cutting-edge cancer research, transforms discoveries into clinical practice and provides education and outreach regarding cancer prevention, detection and treatment.
Rutgers Cancer Institute of New Jersey operates under a “consortium cancer center” matrix as identified by the NCI allowing for formal scientific and academic collaboration with Princeton University and the Institute for Advanced Study. This model unites the best researchers from across the state with one goal to eradicate cancer.
The Cancer Institute’s research base spans six key programmatic areas: Cell Death and Survival Signaling; Genomic Instability and Tumor Progression; Cancer Pharmacology and Preclinical Therapeutics; Clinical Investigations; Carcinogenesis and Chemoprevention; and Cancer Prevention and Control. Research is currently being conducted in areas including: Precision medicine, systems biology, oncogenesis, epidemiology, chemical carcinogenesis, tumor virology and immunology, autophagy, drug development and resistance, the relationship between cellular and genetic alterations and tumor development, population science, cancer control and prevention, bioinformatics, and cancer genomics.
The Cancer Institute of New Jersey offers world-class quality cancer care providing the most advanced medicines and treatment options for patients in its New Brunswick facility as well as at its Network of sixteen hospitals across the state. Together with the Network of hospitals, the Cancer Institute of New Jersey provides care for approximately one-third of all cancer patients in the State of New Jersey.
A dedicated team of nationally renowned specialists including medical oncologists, surgical oncologists, radiation oncologists, social workers, nutritionists, and nurses identify and meet the needs of the individual patient. Each multidisciplinary team focuses on a specific disease and is led by a physician who is a clinical and academic expert in the cause and treatment of that disease.
Multidisciplinary, clinical programs at the Cancer Institute of New Jersey include: Stacy Goldstein Breast Cancer Center, Gastrointestinal/Hepatobiliary Oncology Program, Fannie E. Rippel Center for Women’s Reproductive Cancers, Leukemia/Lymphoma/Hematologic Malignancies, Liver Cancer and Bile Duct Cancer Care Program, Melanoma and Soft Tissue Oncology Program, Neuro-oncology Program, Pediatric Hematology/Oncology Program, Phase I/Developmental Therapeutics Program, Prostate Cancer Program, Stem Cell Transplantation Program, Thoracic Oncology Program, and Urologic Oncology Program.
There are currently several types of clinical trials currently underway at the Cancer Institute of New Jersey including treatment, prevention, screening and behavioral/quality of life. As New Jersey’s only NCI- designated Comprehensive Cancer Center, patients have access to treatment options not available at other institutions within the state.